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Background: Eczema is a prevalent skin disease that is mainly characterized by systemic deviation of immune
response and defective epidermal barrier. Th2 cytokines, such as IL-13 and transcription factor STAT6 are key
elements in the inflammatory response that characterize allergic disorders, including eczema. Previous genetic
association studies showed inconsistent results for the association of single nucleotide polymorphisms (SNPs) with
eczema. Our aim was to investigate whether SNPs in IL13 and STAT6 genes, which share a biological pathway, have
an interactive effect on eczema risk.
Methods: Data from two independent population-based studies were analyzed, namely the Isle of Wight birth
cohort study (IOW; n = 1,456) and for the purpose of replication the Swansea PAPA (Poblogaeth Asthma Prifysgol
Abertawe; n = 1,445) cross-sectional study. Log-binomial regressions were applied to (i) account for the interaction
between IL13 (rs20541) and STAT6 (rs1059513) polymorphisms and (ii) estimate the combined effect, in terms of risk
ratios (RRs), of both risk factors on the risk of eczema.
Results: Under a dominant genetic model, the interaction term [IL13 (rs20541) × STAT6 (rs1059513)] was statistically
significant in both studies (IOW: adjusted Pinteraction = 0.046; PAPA: Pinteraction = 0.037). The assessment of the
combined effect associated with having risk genotypes in both SNPs yielded a 1.52-fold increased risk of eczema in the
IOW study (95% confidence interval (CI): 1.05 – 2.20; P = 0.028) and a 2.01-fold higher risk of eczema (95% CI: 1.29 – 3.12;
P = 0.002) in the PAPA study population.
Conclusions: Our study adds to the current knowledge of genetic susceptibility by demonstrating for the first time an
interactive effect between SNPs in IL13 (rs20541) and STAT6 (rs1059513) on the occurrence of eczema in two
independent samples. Findings of this report further support the emerging evidence that points toward the existence
of genetic effects that occur via complex networks involving gene-gene interactions (epistasis).
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The elevated prevalence of eczema among children (15%
to 30%) and adults (2% to 10%) makes this skin disorder
a public-health concern by placing heavy economic bur-
den on families and societies [1-3]. Eczema is an inflam-
matory skin disorder that is characterized by disrupted
epidermal barrier function, immunoglobulin E (IgE)-* Correspondence: karmaus1@memphis.edu
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reproduction in any medium, provided the ormediated sensitization to food and environmental aller-
gens (i.e., allergic sensitization), and a relapsing–remit-
ting combination of skin dryness and itching [2,4]. The
identification of loss-of-function variants in the filaggrin
gene (FLG) caused a shift in the research paradigm from
mainly focusing on immune related genes to genetic
factors that regulate the formation of the epidermal
barrier [5]. Controversially, however, existing and
evolving evidence suggests that type-2 T helper (Th2)
cytokines can modulate the expression of proteins thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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epidermal barrier [6-8].
Chromosome 5q31-33 harbors genes, including inter-
leukin 4 (IL4) and interleukin 13 (IL13), that encode Th2
cytokines, which are involved in the regulation of IgE syn-
thesis and manifestation of allergic disorders [1,2,9,10].
Th2 cytokines, IL-4 and IL-13, exert their biological effect
through the activation of the transcription factor STAT6
(signal transducer and activator of transcription 6), which
is encoded on chromosome 12q13-24 [9]. Briefly, the
binding of IL-4/IL-13 to their respective membrane recep-
tor leads to the activation of STAT6 by a phosphorylation
process [11,12]. Once activated, STAT6 homodimers
rapidly translocate to the nucleus and induce or sup-
press the transcription of target genes [11-13]. Among
the various target genes of STAT6 are the genes located
in the epidermal differentiation complex, which refers
to a genomic region containing a cluster of genes that
are critical for the development of functional skin
barrier [6,13,14]. Hence, altered STAT6 activation may
contribute to the major hallmarks of eczema: (i) allergic
sensitization and (ii) impaired epidermal barrier.
Even though IL-4 and IL-13 share many biological
functions and signal through a common receptor sub-
unit (IL-4 receptor α chain), it has been suggested that
IL-13 is more important than IL-4 in mediating allergic
inflammation [15,16]. Genetic variants within the IL13
gene have been associated with different allergic pheno-
types, with the non-synonymous coding variant rs20541
(R130Q) being the most replicated [9,16]. More import-
antly, Vladich et al. demonstrated that the IL13 rs20541
130Q variant is more active than the 130R wild-type in
inducing STAT6 phosphorylation/activation [17,18]. In
addition to the role of IL13 genetic polymorphisms in
allergic responses, genetic variants in STAT6 gene have
been linked to multiple allergic phenotypes [19-21]. A
recent genome-wide association study (GWAS) showed
that a single nucleotide polymorphism (SNP) in STAT6
(rs1059513; tagging SNP) is associated with serum total
IgE levels [22].
Therefore, based on the aforementioned investigations
we hypothesize that a complex gene-gene interaction
(epistasis) between IL13 and STAT6 genes could be im-
portant in the pathogenesis of eczema. Our search of the
literature indicated a lack of studies investigating the
possible interaction between genetic variants in IL13 and
STAT6 genes in relation to eczema risk. The purpose of
this study was to determine whether an interaction be-
tween rs20541 in IL13 and rs1059513 in STAT6 on
eczema risk exists. The investigation was conducted in
two independent population-based studies, namely the
Isle of Wight birth cohort (IOW) and the Swansea PAPA
(Poblogaeth Asthma Prifysgol Abertawe) cross-sectional
study.Methods
Isle of Wight study
Study population and characteristics
A whole population birth cohort was established on the
Isle of Wight, UK, in 1989 to prospectively study the
natural history of allergic diseases from birth to 18 years
of age. The island is close to the British mainland, semi-
rural, and without heavy industry. Both the Isle of
Wight and the study population are 99% Caucasian.
Ethics approvals were obtained from the Isle of Wight
Local Research Ethics Committee (now named the
National Research Ethics Service, NRES Committee
South Central – Southampton B) at recruitment and for
the 1, 2, 4, 10 and 18 years follow-up (06/Q1701/34). Of
the 1,536 children born between January 1, 1989, and
February 28, 1990, written informed consent was obtained
from parents to enrol 1,456 newborns. Children were
followed up at the ages of 1 (n = 1,167), 2 (n = 1,174), 4
(n = 1,218), 10 (n = 1,373), and 18 years (n = 1,313). De-
tailed questionnaires were completed for each child at
each follow-up. When a visit was not possible, a telephone
questionnaire was completed or a postal questionnaire
sent for completion and return.
In all assessments of the Isle of Wight birth cohort,
eczema was defined as chronic or chronically relapsing,
itchy dermatitis lasting more than 6 weeks with character-
istic morphology and distribution [23], following Hanifin
and Rajka criteria [24]. Since the 1-year and 2-year
follow-up data on eczema were collected in a relatively
small time window, we combined them for analytic
purposes (reported as 1-or-2 years).
Genotyping
DNA was extracted from blood or saliva samples from
IOW cohort subjects (n = 1,211). Seven SNPs in the IL13
gene were selected for genotyping using a tagging strategy
implemented in Haploview using HapMap Caucasian
data (Hapmap Data PhaseIII/Rel#2, Feb09, on NCBI
B36 assembly, dbSNP b126) [25]. One SNP in STAT6
was selected for replication purposes. DNA samples
were interrogated using GoldenGate Genotyping Assays
(Illumina, Inc, SanDiego, CA) on the BeadXpress
Veracode bead platform (Illumina, Inc, SanDiego, CA)
per Illumina’s protocol. Data were analyzed using the
genotyping module of the GenomeStudio Software
package (Illumina, Inc, SanDiego, CA). DNA from each
subject plus 37 replicate samples, genotyped for control
purposes, were analyzed for a total of 1,248 samples
(trios were not available). The quality threshold for al-
lele determination across samples was set at a GenCall
score >0.25 with n = 1,227 samples retained for further
analysis. Analysis of each locus included reclustering of
genotyping data using our project data to define genotype
cluster positions with additional manual reclustering to
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of the distribution of the GenCall scores across all geno-
types (50% GC score). GenCall score is a quality metric
of the Illumina GenomeStudio software that indicates
the reliability of the genotypes called on SNP arrays,
with scores ranging from 0.0 to 1.0. The proprietary
algorithm for converting raw allele intensities into
genotypes considers angle of the clusters, dispersion of
clusters, overlap between clusters, and intensity. Geno-
types with lower GenCall scores are located furthest
from the center of the cluster. For the analyzed STAT6
and IL13 SNPs the sample call rates were over 95.5%.
GenCall scores and other quality metrics for SNPs
rs20541 and rs1059513 are reported in Additional file 1:
Table S1.Swansea PAPA study
Study population and characteristics
PAPA (Poblogaeth Asthma Prifysgol Abertawe, Swansea
University Asthma Population) is a cross-sectional
population-based study. The study group comprised
1,445 unselected Caucasian volunteers (aged 18–30)
from students and staff at Swansea University and
Singleton Hospital, Swansea, United Kingdom. Eczema
was defined by a positive response to ‘Have you ever
had eczema?’ and further defined by whether partici-
pants currently had symptoms using a validated ques-
tionnaire [26].Genotyping
DNA was extracted from blood samples provided by the
PAPA population subjects (n = 1445). Eight and seven
variants in IL13 and STAT6 genes, respectively, that were
reported to be common in populations of European an-
cestry and/or showed potential association with allergic
phenotypes were selected for genotyping. In order to en-
sure sufficient heterozygosity in our population, variant
selection was refined by genotyping a small sample of
our population for the selected SNPs of interest by auto-
mated DNA sequencing (ABI PRISMTM 310 Gene Ana-
lyser). Following SNP selection, genotyping of selected
SNPs was performed by KBioscience (www.kbioscience.
co.uk) using a fluorescence-based competitive allele-
specific PCR system (KASPar). This proprietary system
has been developed from the Ampliflour system. SNP
Call rates were over 98% for all variants (Additional file 1:
Table S1). A random sample of the population (n = 30)
underwent in-house automated DNA sequencing (ABI
PRISM 310 Gene Analyzer) with results validated against
the overall genotyping results for the population and re-
sults were concordant (trios were not available). Randomly
selected samples were also analyzed in duplicate by
KBioscience to provide further validation. Blank cells wereincluded on each 96-well plate (sterile water) providing
negative controls.
Statistical analysis
Period prevalence of eczema in the IOW study was de-
termined for each follow-up (1-or-2, 4, 10, and 18 years)
by dividing the number of participants with eczema by
the total number of individuals who participated in the
respective follow-up. Similarly, the proportion of partici-
pants with eczema in the PAPA study was determined.
In both studies, proportion of individuals with eczema
was further stratified by IL13 (rs20541) and STAT6
(rs1059513) SNP genotypes. In this report we limited
our analysis to a single SNP in each gene due to their
known relevance to characteristics of the outcome
under-investigation (eczema) and their availability in
both studies. The STAT6 tagging SNP rs1059513 is the
only common SNP in STAT6 that had been genotyped
in both studies. In regard to IL13, four SNPs were in
common between the two studies, namely rs20541,
rs1800925, rs1295685, and rs1881457. In both the IOW
and PAPA studies the four SNPs are in medium to high
linkage disequilibrium (D′ values: IOW: 52 – 99; PAPA:
53 – 99; r2 values: IOW: 26 – 97; PAPA: 26 – 99). This
observation of elevated linkage disequilibrium between
SNPs in IL13 gene had been reported previously [17,27].
Due to the moderate to high linkage disequilibrium be-
tween the four SNPs we restricted our analysis to the
functional (non-synonymous) SNP rs20541, which in
turn is also a proxy of other SNPs in the region. Devi-
ation from Hardy-Weinberg Equilibrium (HWE) was
tested by conducting χ2 goodness-of-fit test for genotype
frequencies in both study populations. A p-value < 0.05
was used as an indicator for possible violation of HWE.
Odds ratios are likely to overestimate the risk ratios
due to the fact that the prevalence of eczema is common
(> 10%) in most of the strata used in our analysis [28].
To evaluate associations between SNP genotypes and ec-
zema, log-binomial regression was applied to estimate
risk ratios (RRs) and 95% confidence intervals (CIs). Ex-
ponentiating coefficients associated with explanatory
variables (i.e., SNP genotypes) estimated by log-binomial
regression with a log link function allowed us to directly
estimate RRs [28]. To estimate the overall effect of SNP
genotypes on eczema, which was repeatedly measured at
1-or-2, 4, 10, and 18 years in the IOW study, we applied
generalized estimating equation (GEE) method [29]. The
GEE approach accounts for the correlated observations
and the within-child effect by employing a covariance
matrix solved through an iterative estimating process
based on a working correlation matrix [29]. Log-
binomial models were estimated using the GENMOD
procedure in SAS 9.2 (SAS, Gary, NC, USA). In all stat-
istical models age and sex were included as potential
Table 1 Characteristics of the IOW and PAPA study
populations and description of the SNPs investigated
Attribute IOW study % (n/total) PAPA study % (n/total)
Age range in years 1 to 18 18 to 30
Gender
Male 51.2 (786/1536) 48.3 (698/1445)
Female 48.8 (750/1536) 51.7 (747/1445)
Eczema prevalence 10.3 (147/1435)
1-or-2 yr 14.2 (196/1377)
4 yr 11.9 (145/1214)
10 yr 13.7 (186/1359)
18 yr 12.3 (161/1307)
IL13 (rs20541)
GG 65.0 (747/1149) 68.7 (973/1416)
AG 31.7 (364/1149) 28.3 (400/1416)
AA 3.3 (38/1149) 3.0 (43/1416)
MAF (allele A) 0.192 0.172
HWE p-value 0.450 0.861
STAT6 (rs1059513)
TT 79.6 (921/1157) 76.9 (1090/1418)
TC 19.5 (225/1157) 21.8 (309/1418)
CC 0.95 (11/1157) 1.3 (19/1418)
MAF (allele C) 0.108 0.122
HWE p-value 0.501 0.693
MAF =Minor allele frequency.
HWE = Hardy-Weinberg equilibrium.
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istical significance.
In a first exploratory step, the associations between ge-
notypes of the two SNPs and eczema were explored
using co-dominant, dominant, recessive, and additive
genetic models. We applied log-binomial regression
models to obtain RRs for eczema relative to SNPs in
IL13 and STAT6 separately. Although, results of this step
are not the focus of this article, controlling for false-
positive findings was performed using the false discovery
rate (FDR) method [30]. However, the aim of this study is
to test the statistical interaction of the two SNPs for the
risk of eczema. Therefore, in the discovery study using the
IOW cohort, log-binomial regression models {RR = exp
(β1 × IL13 + β2 × STAT6 + β3 × [IL13 × STAT6])} were
conducted to evaluate the statistical interaction between
the SNPs of the two genes under four genetic models (co-
dominant, dominant, recessive, and additive). To control
for false-positive interactions, the FDR method was ap-
plied to obtain adjusted p-values associated with the inter-
action terms. In the replication study, i.e. the PAPA study,
we only tested the statistical interaction between the two
SNPs under the genetic model that gained statistical sig-
nificance in the discovery study. Following the concept of
replication, no correction for multiple testing was needed
in the replication study (one model was tested for inter-
action). The interaction term (β3 × [IL13 × STAT6]) was
used to estimate the additional effect of two co-occurring
risk factors on the health outcome above and beyond
their individual effects. The term “combined effect” was
used to describe the joint impact of two individual risk
factors plus their interaction on the occurrence of the
outcome (eczema). We also applied an alternate ap-
proach to estimate the combined effect of both risk fac-
tors; we compared the risk of eczema in individuals who
have both risk factors (IL13 and STAT6 risk genotypes)
to the risk of individuals who have neither (IL13 and
STAT6 wild genotypes). This approach was referred to
as the “combined effect – stratification”.
Results
The period prevalence of eczema in the IOW study
ranged from 11.9% to 14.2% during the first 18 years of
life. In the PAPA study, 10.3% of the young adults (median
age of 20 years) were affected by eczema (Table 1). In both
studies, genotype frequencies of IL13 (rs20541) and STAT6
(rs1059513) polymorphisms were concordant with Hardy-
Weinberg equilibrium. Moreover, allele frequencies were
comparable between the two studies and with data from
the SNP database (dbSNP) for populations of European
ancestry.
In the first exploratory step analyzing main effects
only, under a co-dominant model, the AG and AA geno-
types of IL13 rs20541 were not statistically significantlyassociated with eczema when compared to the reference
genotype GG in both populations (Table 2). In the IOW
study, the homozygous genotype for the minor allele
CC of STAT6 rs1059513 was significantly associated
with eczema in the repeated measurements analysis when
compared to the non-risk genotype TT (RR = 2.21; 95% CI:
1.05 – 4.66). However, this association did not remain sta-
tistically significant after penalizing its p-value for multiple
testing (adjusted p-value = 0.857). Similarly, under the co-
dominant model STAT6 rs1059513 was not associated with
eczema in the PAPA study. In the dominant model, individ-
uals carrying the AG or AA genotype of IL13 SNP rs20541
did not have increased risk of eczema when compared to
those with the GG genotype in either population (Table 2).
Similarly, there was no main effect of STAT6 SNP
rs1059513 and eczema in the dominant model in either
population.
In the discovery step, to determine whether IL13
(rs20541) and STAT6 (rs1059513) SNP genotypes have
an interactive effect on the risk for eczema, four genetic
models (co-dominant, dominant, recessive, and additive)
were used to test for statistical interaction (IL13 ×
STAT6) in the IOW study. After adjusting for multiple
testing, using FDR method, only the interaction term
Table 2 Associations of IL13 and STAT6 SNPs genotypes with eczema: results from IOW and PAPA studies
Gene (SNP rs no.) Model Genotype Eczema % (n/total) RR† 95% CI
IL13 (rs20541)
IOW study‡ Co-dominant GG 12.8 (357/2781) 1.00 –
AG 14.3 (194/1357) 1.10 0.88 – 1.38
AA 16.9 (24/142) 1.37 0.83 – 2.25
p-trend* 0.08
Dominant GG 12.8 (357/2781) 1.00 –
AG/AA 14.5 (218/1499) 1.13 0.91 – 1.40
PAPA study Co-dominant GG 9.5 (92/967) 1.00 –
AG 12.3 (49/397) 1.27 0.92 – 1.76
AA 11.6 (5/43) 1.14 0.49 – 2.68
p-trend* 0.147
Dominant GG 9.5 (92/967) 1.00 –
AG/AA 12.3 (54/440) 1.26 0.91 – 1.73
STAT6 (rs1059513)
IOW study‡ Co-dominant TT 13.6 (467/3438) 1.00 –
TC 12.8 (106/830) 0.92 0.70– 1.20
CC 28.6 (12/42) 2.21 1.05 – 4.66$
p-trend* 0.54
Dominant TT 13.6 (467/3438) 1.00 –
TC/CC 13.5 (118/872) 0.98 0.75 – 1.27
PAPA study Co-dominant TT 9.8 (106/1082) 1.00 –
TC 12.3 (38/308) 1.33 0.94 – 1.88
CC 10.5 (2/19) 1.16 0.31 – 4.30
p-trend* 0.243
Dominant TT 9.8 (106/1082) 1.00 –
TC/CC 12.2 (40/327) 1.32 0.93 – 1.86
† Association adjusted for gender and age at follow up.
* Based on Cochran-Armitage Trend Test.
‡ Association results for the IOW study were based on repeated measurement analysis (GEE models), which utilized data collected at the 1-or-2, 4, 10, and
18 years follow-ups.
$ The association was not statistically significant after adjusting for multiple testing (adjusted p-value = 0.857).
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significant (adjusted Pinteraction = 0.046; Table 3). In the
replication step using the PAPA study, we only tested
the interaction term between (IL13 × STAT6) under the
dominant genetic model. In line with the IOW study
results, this interaction was replicated in the PAPA study
(Pinteraction = 0.037; Table 3). In addition to the inter-
action term, the combined effect, defined as the risk of
eczema among individuals with AG/AA (rs20541) and
TC/CC (rs1059513) genotypes compared to the risk of
eczema among individuals with GG (rs20541) and TT
(rs1059513) genotypes, was estimated using two ap-
proaches. The modeling approach took into account the
main effects of each SNP plus their interaction effect
using the whole sample. A stratification approach was
applied using stratification method in which individuals
with risk genotypes for both SNPs were groupedtogether and those with non-risk genotypes formed the
referent group. In the IOW study, the combined effect
based on the modeling approach yielded a 1.41-fold
trend for increased risk of eczema which was borderline
for being statistically significant (P = 0.063). The stratifica-
tion method showed that the combined effect associated
with having risk genotypes in both SNPs demonstrated
statistical significance (RR = 1.52; P = 0.028). Concordant
with results from the IOW study, in the PAPA study, both
the modeling and stratification approaches estimated a
significant combined effect of an approximately 2-fold in-
creased risk of having eczema (Modeling: P = 0.003; Strati-
fication: P = 0.002; Table 3).
Discussion
Eczema is a multifactorial disorder that is believed to
be the result of a complex interaction between genetic,
Table 3 Interaction and combined effects of IL13 (rs20541) and STAT6 (rs1059513) single nucleotide polymorphisms on
eczema risk: results from IOW and PAPA studies
IOW (discovery) study† – Dominant model
Variable Coefficient RR$ 95% CI p-value
IL13 (AG/AA vs. GG) −0.008 0.99 0.53 – 1.09 0.952
STAT6 (TC/CC vs. TT) −0.278 0.76 0.77 – 1.27 0.135
Interaction (IL13 × STAT6) 0.630 1.88 1.10 – 3.19 0.046£
Combined effect – Modeling* 0.344 1.41 0.98 – 2.03 0.063
Combined effect – Stratification¶ 0.418 1.52 1.05 – 2.20 0.028
PAPA (replication) Study – Dominant model
IL13 (AG/AA vs. GG) −0.043 0.96 0.64 – 1.43 0.833
STAT6 (TC/CC vs. TT) −0.025 0.98 0.60 – 1.58 0.920
Interaction (IL13 × STAT6) 0.754 2.13 1.05 – 4.31 0.037
Combined effect – Modeling‡ 0.686 1.99 1.27 – 3.11 0.003
Combined effect – Stratification¶ 0.698 2.01 1.29 – 3.12 0.002
† Association results for the IOW study were based on repeated measurement analysis (GEE models), which utilized data collected at the 1-or-2, 4, 10, and
18 years follow-ups.
$ Association adjusted for gender and age at follow up.
£ Adjusted for multiple testing using the false discovery rate method p-value.
* Combined effect – Modeling RR was estimated as: RR = exp(−0.008 – 0.278 + 0.630).
‡ Combined effect – Modeling RR was estimated as: RR = exp(−0.043 – 0.025 + 0.754).
¶ Combined effect – Stratification RR was estimated by pooling together individuals with risk genotypes for both SNPs and those with non-risk genotypes formed
the referent group.
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heritability and clustering of eczema within families
highlight the importance of the genetic component in
disease pathogenesis [31]. Genes that regulate the epi-
dermal barrier formation and immunological response
have been implicated in eczema development [9,31,32].
This study adds to the current knowledge of genetic
susceptibility by demonstrating for the first time an
interactive effect between SNPs in IL13 (rs20541) and
STAT6 (rs1059513) on the occurrence of eczema in
two independent samples. Our results emphasize the
importance of accounting for the effect of multiple
genes (epistasis/gene-gene interaction) when assessing the
genetic contribution in the development of complex
diseases, such as eczema.
The current study investigated the association of SNPs
in IL13 (rs20541) and STAT6 (rs1059513) genes separ-
ately and jointly (gene-gene interaction) on the risk for
eczema in two independent population-based studies.
The SNP rs20541 was not associated with eczema in ei-
ther the IOW nor PAPA studies. Similar results were
obtained for the SNP rs1059513, which showed no asso-
ciation in both the IOW and PAPA studies. However, a
consistent significant statistical interaction under a dom-
inant genetic model between IL13 (rs20541) and STAT6
(rs1059513) on the risk of eczema was demonstrated in
both studies. Participants in the IOW study who carried
the risk genotypes for both SNPs had a 1.52-fold in-
creased risk for eczema during the first 18 years of life.
Similarly, in the PAPA population, those with the riskgenotypes for both SNPs had a 2.01-fold higher risk of
eczema than those with wild-type genotypes for both
SNPs. Our investigation demonstrates an important
combined effect of genetic variants within IL13 and
STAT6 genes on eczema risk.
The longitudinal design of the Isle of Wight birth co-
hort study that covered the first 18 years of life is a
major strength of our study. Throughout all assess-
ments, the proportion of participation remained high,
which ruled-out a major bias due to loss-to-follow up.
Misclassification of eczema cases is minimal since a high
proportion of subjects showed typical manifestation of
eczema in usual locations (antecubital or popliteal fossae,
ankles, face or neck for 97% at 1 year, 91% at 2 years, 75%
at 4 years, 86% at 10 years and 76% at 18 years) [33]. In
addition, the prevalence of eczema in our cohort (13.7%
at age 10 years and 12.3% at age 18 years) is comparable
to results from the International Study of Asthma and
Allergies in Childhood aged 13–14 years in the United
Kingdom (UK) (14.7% phase one and 10.6% phase three)
and other studies conducted in the UK [34-36].
A major strength of the PAPA study was the large
number of young adult volunteers within a relatively
narrow age range. Participants were comprehensively
phenotyped with relation to clinical allergic/atopic phe-
notypes. Eczema was self-reported by validated question-
naire which is considered as robust for epidemiological
investigations [26]. Self-reporting might have led to some
misclassification but this was minimized by the same
physician being present when completing questionnaires
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lence (10.3%) in young adults (median age 20 years) in the
study is comparable to European prevalence in a
multicentre study (8.8%) in a slightly older age group (27–
35 years), indicating that any potential misclassification was
minor and that our unselected population was a represen-
tative sample [37]. In both studies, participants were not
aware of their genetic status, nor were the medical investi-
gators. Hence misclassification was non-differential, which
is no threat to validity and tends to reduce the relative esti-
mates of the relative risks.
The minor allele frequency (MAF) of rs20541 was
comparable across the two study populations (IOW:
19.2%; PAPA: 17.2%). Moreover, allele frequencies were
comparable with data from the SNP database (dbSNP)
for populations of European ancestry, which ranged
from 14% to 23% based on the HapMap project data. In
regard to rs1059513, the MAF was similar between the
two study populations (IOW: 10.8%; PAPA: 12.2%) and
within the range for populations of European ancestry
(6% to 18%).
Genetic variants in the IL13 gene region have shown
association with asthma, eczema, allergic rhinitis, and
increased IgE levels in multiple studies of diverse race/
ethnic backgrounds [16,27]. Similarly, SNPs in the gen-
omic region of the STAT6 gene had been reported to be
associated with allergic phenotypes, especially regulation
of IgE production [22,38]. However, the previously noted
associations were not consistent throughout the literature.
Such inconsistencies that hamper genetic association stud-
ies can be explained, at least in part, by population di-
versity, phenotype heterogeneity, lack of independent
replication of genotype-phenotype associations, or not
accounting for possible gene-gene or gene-environment
interactions. Furthermore, the small to modest effect sizes
(e.g., risk/odds ratios from 1.1 to 1.5) associated with gen-
etic variants on the risk of complex diseases found in
GWAS can possibly be improved if interaction of multiple
variants is considered [39,40]. In this report we have in-
vestigated the interactive effect between rs20541 and
rs1059513 on eczema risk for the following reasons: (i) the
functional variant (rs20541) of IL13 was associated with
increased IL-13 biological activity [27], (ii) IL13 rs20541
leads to increased activation of STAT6 [17], (iii) STAT6
rs1059513 is associated with IgE dysregulation [22], (iv) the
interaction between SNPs in IL13 and STAT6 on the risk
for eczema have not, to our knowledge, been studied pre-
viously, however, (v) studies have shown that genetic vari-
ants within IL13 and STAT6 have interactive effects on IgE
synthesis [41] and asthma risk [42]. Genotyping of these
two SNPs in both the IOW and PAPA studies facilitated
the replication of our findings.
A limitation to our study is that only two SNPs (one
in each gene) were investigated. However, as previouslymentioned, their importance in the pathogenesis of aller-
gic phenotypes is well established [10,17,22,27]. There-
fore, results of this report should stimulate future
studies to incorporate a wider range of SNPs as such an
approach might reveal larger effect sizes. While no formal
tests of population stratification were carried out as data
from ancestry informative makers were not available, both
study populations were of UK Caucasian ancestry, which
reduces the chance that the observed associations are a
result of population stratification. Although the two study
populations differed in their age group structure (IOW
study: longitudinal assessment covering the first 18 years
of life; PAPA study: participants aged 18 to 30 years), we
were able to find comparable interaction results across
the two studies. Slightly different epidemiologic methods,
12-month period prevalence (IOW) and point prevalence
(PAPA), were used to measure disease occurrence. How-
ever, the comparable proportion of individuals with ec-
zema in the IOW study (12.3% at 18 years) and in the
PAPA study (10.3% between 18 to 30 years) is a sound
indication that phenotypic heterogeneity is not an issue.
The use of log binomial regression to estimate risk ra-
tios could raise issues since it is less stable than logistic
regression [43]. However, we have compared the per-
formance of both methods (data not shown) and decided
to present estimates obtained from the log binomial
regression due to the similar results provided by both
methods. The advantage of using log binomial regression
is that it allows direct estimation of adjusted risk ratios;
whereas, logistic regression estimates odds ratios which
is vulnerable to overestimate the relative risk when the
prevalence of the outcome is not rare in all analyzed
strata of the outcome [28].
Eczema is a complex disease in which both immuno-
logical imbalances and dysfunctional skin barrier play a
major role in its pathogenesis [44]. The discovery of
loss-of-function variants in the filaggrin gene and their
successful association with eczema in multiple studies
has shed light on the importance of skin barrier genetics.
However, inflammatory Th2 cytokines, such as IL-13
and IL-4, have been shown to modulate the expression of
keratinocyte genes leading to epidermal thickening and
impaired skin barrier [45]. Furthermore, it has been shown
that the down-regulation of epidermis-differentiation re-
lated genes by Th2 cytokines is a STAT6-dependent
mechanism [6]. Therefore, Th2 cytokines could contribute
to the immunologic disturbance and dysfunctional skin
barrier that characterize eczema.
Conclusions
The current study demonstrates that gene-gene inter-
action (epistasis) between IL13 and STAT6 polymorphisms
contributes significantly to the genetic determination of
eczema in two independent British epidemiological
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in addition to individual SNP analysis, will provide a more
comprehensive picture of how genetic variants of genes
sharing a biological pathway may interact to produce com-
plex disorders, such as eczema. Therefore, future studies
should move beyond the one SNP by one SNP approach
taken so far, and simultaneously interrogate multiple genes
within a biological pathway to shed more light on the con-
tribution of genetic susceptibility.
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